id: NEW:buprenorphine_naloxone_combination_treatment_to_neonatal_abstinence_syndrome_nas
name: Buprenorphine-Naloxone Combination Treatment During Pregnancy â†’ Neonatal Abstinence Syndrome (NAS)
from_node:
  node_id: NEW:buprenorphine_naloxone_combination_treatment
  node_name: Buprenorphine-Naloxone Combination Treatment During Pregnancy
to_node:
  node_id: neonatal_abstinence_syndrome_nas
  node_name: Neonatal Abstinence Syndrome (NAS)
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Pregnant individuals with opioid use disorder receive buprenorphine-naloxone combination treatment'
- 'Step 2: Naloxone component has limited oral bioavailability, reducing systemic opioid exposure when
  taken as prescribed'
- 'Step 3: Potentially different pharmacokinetic profile leads to altered fetal opioid exposure patterns'
- 'Step 4: Reduced or modified in utero opioid exposure decreases severity of neonatal withdrawal symptoms'
- 'Step 5: Lower rates of neonatal abstinence syndrome requiring treatment in exposed infants'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Loreen Straub et al. 2024. "Comparative Safety of In Utero Exposure to Buprenorphine
    Combined With Naloxone vs Buprenorphine Alone.." https://doi.org/10.1001/jama.2024.11501
  supporting_citations:
  - Additional citations require full-text access - Abstract references limited perinatal safety data
    on combination product
  - Additional citations require full-text access - Study builds on existing buprenorphine monotherapy
    pregnancy research
  - Additional citations require full-text access - Medicaid utilization data from 2000-2018 analyzed
  doi: 10.1001/jama.2024.11501
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Prenatal exposure to buprenorphine combined with naloxone was associated with a 23% lower
  risk of neonatal abstinence syndrome compared to buprenorphine alone (absolute risk 37.4% vs 55.8%).
quantitative_effects:
  effect_size:
    value: 0.77
    type: relative_risk
    ci_lower: 0.7
    ci_upper: 0.84
  sample_size: 8695
moderators:
- name: Medicaid insurance status
  direction: strengthens
  strength: moderate
  description: Study population limited to Medicaid beneficiaries, who may have different characteristics
    than privately insured populations
structural_competency:
  equity_implications: This mechanism highlights how medication formulation policies and treatment guidelines
    create structural barriers for pregnant individuals with OUD. Historical restriction of combination
    product in pregnancy limited treatment options. Expanding safe treatment options addresses structural
    healthcare access inequities for this vulnerable population. Medicaid population focus reveals safety
    data for economically disadvantaged pregnant individuals.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.683981'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
